118 / 140
240
16. Gallant J, DeJesus E, Arribas J et al. Tenofovir DF, emtricitabine, and
efavirenz vs zidovudine, lamivudine and efavirenz for HIV. N Engl J Med
2006; 354;251-260.
17. Riddler S, Haubrich R, Di Rienzo A et al. Class-sparing regimens for initial
treatment of HIV-1 infection. New Engl J Med 2008; 358:2095-2106.
18. Strategies for Management of Antirretroviral Therapy (SMART) Study
Group. CD4+ count-guided interruption of antiviral treatment. N Engl J
Med 2006; 355:2283-2296.
19. Pugliese A, Isnardi D, Saini A, et al. Impact of highly active antiretroviral
therapy in HIV-positive patients with cardiac involvement. J Infect 2000,
40:282-4.
20. Eckardt B, Glesby M. Antirretroviral therapy and cardiovascular risk: are
some medications cardioprotective?. Curr Opin HIV AIDS 2008; 3:226-
233.
21. Baker J, Henry K, Neaton J. The consequences of HIV in fection and retroviral
therapy use for cardiovascular diseases risk: shifting paradigms. Curr Opin
HIV AIDS 2009; 4:176-82.
22. Skiest D, Cohen C, Khanlou H et al. Efficacy and safety of switching
suppressed patients with elevated triglycerides from Lopinavir/Ritonavir
or Fosamprenavir/Ritonavir to Atazanavir/Ritonavir or Darunavbir/
Ritonavir based therapy: The LARD study. HIV and AIDS Review 2012;
11:77-83.
23. Yovanovich J. Manifestaciones cardiovasculares del VIH y SIDA. En:
Sepúlveda C y Afani A. SIDA, 4ª Edición, Santiago, Ed Mediterráneo 2009;
136-144.
24. Mondy K, Gottdiener J, Overton E, Henry K et al. High prevalence of
echocardiographic abnormalities among HIV infected persons in the era
of highly active antiretroviral therapy. Clinical infectious diseases 2011;
52(3): 378-386.
25. Zanni M, Abbara S, Lo J et al. Increased coronary atherosclerotic plaque
vulnerability by coronary computed tomography angiography in
HIV-infected men. AIDS 2013; 27:1263-1272.
[REV. MED. CLIN. CONDES - 2015; 26(2) 234-240]